Zusätzliche Mittel für die Arzneimittelsicherheitsüberwachung von COVID-19-Impfstoffen seit 2020

This question concerns the financial resources allocated to monitoring the safety of COVID-19 vaccines since 2020. It seeks to understand the extent of funding provided for this crucial public health surveillance. The focus is on the additional funds made available, highlighting the importance of robust safety oversight for vaccines and its impact on public trust and health outcomes.